The Filing Desk

Pro Dex

PDEX · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

PDEX · Last close · November 19, 2026
$63.49
Value Pro Dex yourself

Pro Dex's revenue rose 16.4% to $78 million in fiscal 2026. Its operating margin was 16.8%, up from 16.1% a year earlier. Free cash flow was $7 million. It paid out $3 million in dividends and buybacks, 50% of free cash flow. The diluted share count fell 1.3%.

PRO-DEX, INC. Latest fiscal year ended June 30, 2026 10-K filed September 3, 2026 · 0001079973-26-001215 Updated
Revenue
$78M
16.4%
Operating margin
16.8%
0.7 pts
Net income
$14M
52.2%
Free cash flow
$7M
 
Return on capital
19.6%
0.1 pts
Market cap
$210M
Nov 19 close
P/E
17.5x
On $3.63 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Pro Dex does

Pro-Dex designs and makes surgical drivers and shavers: battery-powered and electric handheld tools that can be sterilized in an autoclave and are used mainly in orthopedic, chest and facial bone surgery. It sells mostly to medical device makers and distributors, which sell the tools under their own brands. It also provides engineering, quality and regulatory consulting to customers and makes small air motors for industry.

In fiscal 2026 it derived 98% of its revenue from medical device products and related services. Its sales depend on a few customers: its top three accounted for 92% of sales, and its largest customer alone for 78%. That customer has made purchase commitments through calendar 2028.

In February 2026 the company bought Advanced Precision Machining, a maker in Costa Mesa, California that supplies parts for aerospace and defense and for the company's own devices. It machines its medical products in Irvine, California and assembles them in Tustin, California. It was incorporated in Colorado in 1994.

Its biggest risks, as it describes them

  • A large share of its sales comes from a few customers, so losing one would hurt it badly.
  • Almost all its revenue comes from medical device products and related services.
  • Its largest customer's purchase commitments run only through calendar 2028, with no assurance they will be extended.
  • It must keep developing new and improved products to meet customers' needs.
From Pro Dex's annual report on Form 10-K, filed September 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2026, earnings per share grew 14.2% a year and net income 11.6% a year, as buybacks cut the share count by 20%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments24779
Debt incl. finance leases1413121518
Net debt (negative means net cash)129588
Net debt to EBITDA2.0x1.3x0.6x0.7x0.6x
Debt to equity0.5x0.4x0.4x0.4x0.4x
Interest coverage11.0x10.8x12.8x12.9x16.0x
Current ratio2.7x3.2x2.8x3.2x4.1x
Quick ratio1.6x1.5x1.7x1.7x2.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Pro Dex's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Pro Dex shares on the open market, and 3 insiders sold $2.0 million, $1.8 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026Kirk Richard Lee Van JrChief Executive Officer, DirectorSold plan765$59.36$45,412Form 4
Sep 9, 2026Kirk Richard Lee Van JrChief Executive Officer, DirectorSold plan19,235$60.58$1.2 millionForm 4
Sep 9, 2026Alisha CharltonChief Financial OfficerSold2,300$61.30$140,983Form 4
May 22, 2026Kirk Richard Lee Van JrChief Executive Officer, DirectorSold plan4,128$62.36$257,438Form 4
May 21, 2026Kirk Richard Lee Van JrChief Executive Officer, DirectorSold plan5,872$62.81$368,810Form 4
Mar 16, 2026Angelita Rebamontan DomingoDirectorSold998$47.24$47,146Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score6 of 96 of 97 of 9
Rule of 40—19.3%25.2%
Altman Z''7.068.168.66
Accruals ratio−7.9%18.8%9.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positivePassPassPass
Cash from operations is positivePassFailPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsPassFailPass
Current ratio roseFailPassPass
Share count didn't risePassPassPass
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassFail
F-score6 of 96 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Pro Dex side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Pro DexFY2616.4%16.8%8.7%19.6%0.6x7
Sight SciencesFY25−3.1%−48.0%−38.7%——5Compare
TELA BioFY2515.8%−42.0%−35.7%−190.2%—4Compare
ElectromedFY2615.3%18.8%11.4%———Compare
IRADIMEDFY2514.4%31.2%20.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue22222735384246546778
Revenue growth8.9%2.4%20.9%28.2%9.2%10.6%9.6%16.8%23.7%16.4%
Gross profit781013141313152024
Research and development1222433343
Operating income325745671113
Net income52466572914
Diluted EPS (US$)1.250.370.971.501.571.211.950.602.674.12
Diluted shares (millions)4444444433
Cash flow
Cash from operations3335−2−166−27
Capital expenditure111022——10
Free cash flow3224−4−2——−37
Dividends paid0000000000
Share buybacks0043622443
Acquisitions0000000006
Stock-based compensation0000111111
Balance sheet at fiscal year end
Cash and short-term investments57109524779
Debt incl. finance leases0054131413121518
Total assets16202631404952526174
Total liabilities33812202420222527
Shareholders' equity14171719212532313748
Margins and ratios
Gross margin32.8%35.4%36.0%37.7%35.7%31.2%27.7%27.0%29.3%31.4%
Operating margin12.5%10.7%18.4%20.3%11.9%12.2%12.5%13.3%16.1%16.8%
Net margin23.2%7.2%15.3%17.6%16.2%10.9%15.3%4.0%13.5%17.6%
Free cash flow margin12.0%9.7%7.1%12.7%−10.1%−5.9%——−4.4%8.7%
Rule of 40 (growth + FCF margin)20.8%12.1%28.1%40.9%−0.9%4.6%——19.3%25.2%
Return on capital35.2%15.8%34.5%41.7%17.1%12.4%11.1%15.2%19.7%19.6%
Return on equity45.0%10.5%24.2%33.9%30.7%19.6%24.8%6.8%26.6%32.4%
Return on assets37.0%8.9%18.3%21.6%17.3%10.2%14.0%4.1%15.8%20.1%
Net debt to EBITDA−1.5x−2.5x−0.9x−0.7x1.5x2.0x1.3x0.6x0.7x0.6x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Pro Dex's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Pro Dex.